Tyrosinase inhibitor whitening composition containing lotus leaf extract as well as preparation method and application of tyrosinase inhibitor whitening composition
By combining plant extracts such as lotus leaf extracts and small molecule peptides and additives, a tyrosinase inhibitor for cosmetics was prepared, which solved the side effects of tyrosinase inhibitors in existing whitening cosmetics and The problem of poor absorption achieves effective whitening and antioxidant effects.
Patent Information
- Application Number
- CN202411154928.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-22
AI Technical Summary
The components used to inhibit tyrosinase in existing whitening cosmetics have side effects or instability, and the skin is poorly absorbed, making it difficult to effectively achieve whitening effects.
Lotus leaf extract, strong red pedigree extract, smudge extract, small molecule peptide and organic phenol as tyrosinase inhibitor compositions, and combine additives through the combined action of plant extract and small molecule peptide. The addition of the product has been prepared a whitening composition that effectively inhibits the activity of tyrosinase, and is used in cosmetics.
It has achieved effective inhibition of tyrosinase activity, has significant whitening and antioxidant effects, improves the effectiveness of cosmetics, and is simple to operate, easy to obtain raw materials, and is suitable for mass production.
Smart Images

Figure BDA0005004672740000091 
Figure BDA0005004672740000101 
Figure BDA0005004672740000111
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cosmetics, and in particular relates to a tyrosinase inhibitor whitening composition containing lotus leaf extract, and a preparation method and application thereof. Background Art
[0002] Melanin is found in human skin, hair and eyes and is an indole polymer. In nature, melanin exists in several different forms, such as eumelanin, neuromelanin, isomelanin, pheomelanin and pyomelanin. Melanin is synthesized in melanocytes and stored in specialized organelles called "melanosomes", from which it is transferred to neighboring keratinocytes to protect them from UV damage. The first step in melanin production is the hydrolysis of L-tyrosine to L-dopa by tyrosinase, which then oxidizes L-dopa to dopaquinone. Tyrosinase-associated proteins oxidize dopaquinone to 5,6-dihydroxyindole or 5,6-dihydroxyindole-2-carboxylic acid, both of which are monomers of eumelanin. Under the action of cysteine, dopaquinone reacts with it to eventually produce pheomelanin.
[0003] Tyrosinase plays an important role in the formation of melanin. Tyrosinase (TYR) is a copper-containing metalloenzyme with a highly conserved double copper binding region. Each copper ion is connected to three histidine residues through a coordination bond to form an active site with a specific structure. The combination of dioxygen and two copper ions allows TYR to exist in three different states: oxidation, reduction, and deoxygenation, thereby playing a catalytic role. TYR plays an important role in pigmentation. It is the rate-limiting enzyme for the synthesis of melanin. Inhibiting the activity of TYR plays an important role in the adjuvant treatment of melanoma and most pigmentation, which also promotes the development of whitening cosmetics.
[0004] In the field of whitening cosmetics, currently the commonly used ingredients that can inhibit the activity of tyrosinase are kojic acid, arbutin, vitamin C, tropolone, hydroquinone, etc. However, most of these whitening additives have side effects to a certain extent. For example, arbutin may be a precursor of hydroquinone, which has toxic side effects on the skin; although kojic acid has a strong inhibitory effect on tyrosinase, it is unstable and may cause cancer if used for a long time; vitamin C and its derivatives are poorly absorbed by the skin and are only effective at high concentrations.
[0005] The main biologically active ingredients of lotus leaves are alkaloids and flavonoids. In addition, it also contains essential oils, tannins, vitamin C, tartaric acid, citric acid, malic acid, oxalic acid, and a variety of trace elements necessary for the human body, such as iron, zinc, copper, and manganese. Lotus leaves have good antioxidant effects. Studies have shown that the methanol extract of lotus leaves has strong antioxidant activity, which is equivalent to BHA and slightly higher than α-tocopherol. The antioxidant effect of lotus leaf extract can replace tocopherol and BHA and be added to cosmetics. It has an antioxidant effect on nutrients such as lecithin, acids, and hydroquinone, thereby improving the effectiveness of cosmetics. And this antioxidant effect can remove free radicals produced in the body and play an anti-aging role. Summary of the invention
[0006] Based on the above, the primary purpose of the present invention is to provide a tyrosinase inhibitor whitening composition containing lotus leaf extract and a preparation method and application thereof, so as to achieve wide application in cosmetics.
[0007] To this end, the present invention provides the following technical solutions.
[0008] One aspect of the present invention provides a tyrosinase inhibitor whitening composition containing lotus leaf extract, wherein the whitening composition is composed of a plant extract, a small molecule peptide and an adjuvant, wherein the mass ratio of the plant extract, the small molecule peptide and the adjuvant is (1-3): (1-1.5): (0.01-0.05).
[0009] In a preferred embodiment of the present invention, the plant extracts include: lotus leaf extract, cymbidium sibiricum extract and buddleja flower extract, and the mass ratio of the lotus leaf extract, cymbidium sibiricum extract and buddleja flower extract is 1:(0-0.5):(0-1).
[0010] In a preferred embodiment of the present invention, the small molecule peptide is heptapeptide I, and the heptapeptide I is heptapeptide-6.
[0011] In a preferred embodiment of the present invention, the small molecule peptide is heptapeptide II, and the heptapeptide II is acetyl heptapeptide-4.
[0012] In a preferred embodiment of the present invention, the auxiliary agent is selected from any one of paeonol, bakuchiol, kaempferol, and 4-butylresorcinol.
[0013] Another aspect of the present invention provides a use of a tyrosinase inhibitor whitening composition containing lotus leaf extract in the preparation of whitening cosmetics.
[0014] In a preferred embodiment of the present invention, the added mass of the tyrosinase inhibitor whitening composition containing lotus leaf extract in the whitening cosmetic is 0.5-5% based on the total mass of the whitening cosmetic.
[0015] In a preferred embodiment of the present invention, the whitening cosmetics include whitening skin care water, whitening essence, whitening lotion or whitening skin care cream.
[0016] In a preferred embodiment of the present invention, the whitening cosmetic further comprises a moisturizer and a thickener.
[0017] In a preferred embodiment of the present invention, the moisturizing agent includes one or a combination of two or more of butylene glycol, panthenol, glycerin, dipropylene glycol, propylene glycol, polyethylene glycol-32, glyceryl polyether-26, and sodium hyaluronate.
[0018] In a preferred embodiment of the present invention, the thickener includes one or a combination of two or more of xanthan gum, behenyl alcohol, ammonium acryloyldimethyltaurate / VP copolymer, polyacrylamide, carbomer, and hydroxyethyl cellulose.
[0019] In a preferred embodiment of the present invention, the whitening cosmetic further comprises a skin conditioner and a solubilizer.
[0020] In a preferred embodiment of the present invention, the skin conditioning agent is selected from one or a combination of two or more of citric acid, ceramide, arginine, resveratrol, and hydrogenated lecithin.
[0021] In a preferred embodiment of the present invention, the solubilizer is selected from one or a combination of two or more of polysorbate-60, polysorbate-20, PEG-40 hydrogenated castor oil, and PEG-60 hydrogenated castor oil.
[0022] By means of the above technical solution, the present invention has at least the following advantages:
[0023] 1. The present invention uses plant extracts and small molecule peptides as tyrosinase inhibitors. Through the combined action of the two components, the tyrosinase activity can be effectively inhibited, thereby achieving whitening and anti-oxidation effects. The composition of the present invention also contains an auxiliary agent, which is an organic phenol. The addition of the auxiliary agent can promote the inhibitory effect of the plant extract and the small molecule peptide on tyrosinase, thereby further improving the whitening effect of the composition.
[0024] 2. The plant extract of the present invention includes lotus leaf extract, strong red gate orchid extract and buddleja extract. In addition to alkaloids and flavonoids, lotus leaf extract also contains essential oils, tannins, vitamin C, tartaric acid, citric acid, malic acid, oxalic acid, etc. It can inhibit the activity of tyrosinase and has anti-oxidation and anti-aging effects. Strong red gate orchid extract has the effects of strengthening the body, unobstructed stomach, analgesia, regulating qi and eliminating phlegm, and expelling insects. Buddleja extract contains a variety of chemical components such as flavonoids, volatile oils, yellow pigments, triterpenes, iridoid glycosides, etc., and has anti-inflammatory, immunomodulatory, hypoglycemic, anti-oxidation, and anti-vascular endothelial cell proliferation.
[0025] 3. The heptapeptide of the present invention includes heptapeptide I and heptapeptide II. The former is heptapeptide-6, which is an active peptide that can reduce fat mass, lose weight, effectively reduce various wrinkles, and improve skin firmness, smoothness, and elasticity; the latter is acetyl heptapeptide-4, which has multiple biological functions, such as promoting the balance of skin microbiota, improving immune response, and enhancing the integrity of physical barriers, which helps to improve the overall health of the skin, enhance the skin's own defense system, and fight sensitivity and inflammation. The exploratory experiments of the present invention show that the direct combined action of these two heptapeptides with plant extracts and adjuvants can effectively inhibit the production of melanin, deposit in the body and on the surface of the skin, and have excellent whitening effects.
[0026] 4. The preparation method of the whitening cosmetic of the present invention is simple to operate, the raw materials are easy to obtain, and batch production is possible.
[0027] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described in detail as follows. DETAILED DESCRIPTION
[0028] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] Unless otherwise specified, the percentage content involved in the present invention refers to mass percentage for solid-liquid mixing and solid-solid mixing, and refers to volume percentage for liquid-liquid mixing.
[0030] Unless otherwise specified, the percentage concentrations referred to in the present invention all refer to final concentrations, which refer to the percentage of the added component in the system after the addition of the component.
[0031] The temperature parameters in the present invention, if not specifically limited, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the precision range controlled by the instrument.
[0032] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods.
[0033] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0034] Unless otherwise specified, the heptapeptide I used in the following examples is heptapeptide-6 and the heptapeptide II is acetyl heptapeptide-4, both of which were purchased from Shanghai Ketide Biotechnology Co., Ltd. Lotus leaf extract was purchased from Fufeng Sinot Biotechnology Co., Ltd.; Strong red gate orchid extract was purchased from Ningxia Vanilla Biotechnology Co., Ltd.; Buddleja bud extract was purchased from Lanzhou Waterless Biotechnology Co., Ltd.
[0035] Embodiment 1:
[0036] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0037] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: the plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 2:1.25:0.03.
[0038] Embodiment 2:
[0039] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.5:1.
[0040] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and bakuchiol are mixed in a mass ratio of 1:1:0.05.
[0041] Embodiment 3:
[0042] Preparation of plant extracts: Lotus leaf extract, Rhododendron robustum extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25):0.5.
[0043] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and kaempferol are mixed in a mass ratio of 3:1.5:0.01.
[0044] Embodiment 4:
[0045] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.5:1.
[0046] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and 4-butylresorcinol are mixed in a mass ratio of 1:1.5:0.01.
[0047] Embodiment 5:
[0048] Preparation of plant extracts: Lotus leaf extract, Rhododendron robustum extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:1.
[0049] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and bakuchiol are mixed in a mass ratio of 3:1.5:0.01.
[0050] Embodiment 6:
[0051] Preparation of plant extracts: Lotus leaf extract, Rhododendron robustum extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.5:0.5.
[0052] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 2:1:0.01.
[0053] Embodiment 7:
[0054] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0055] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide I and kaempferol are mixed in a mass ratio of 2:1.25:0.03.
[0056] Comparative Example 1:
[0057] Preparation of plant extracts: Lotus leaf extract and Rhododendron robustum extract were mixed in a mass ratio of 1:0.25.
[0058] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: the plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 2:1.25:0.03.
[0059] Comparative Example 2:
[0060] Preparation of plant extracts: Mix the lotus leaf extract and the buddleja buddleja flower extract in a mass ratio of 1:0.5.
[0061] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: the plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 2:1.25:0.03.
[0062] Comparative Example 3:
[0063] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: Lotus leaf extract, heptapeptide II and paeonol are mixed in a mass ratio of 2:1.25:0.03.
[0064] Comparative Example 4:
[0065] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: Heptapeptide II and paeonol are mixed in a mass ratio of 1.25:0.03.
[0066] Comparative Example 5:
[0067] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0068] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: the plant extract and paeonol are mixed in a mass ratio of 2:0.03.
[0069] Comparative Example 6:
[0070] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0071] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: the plant extract and heptapeptide II are mixed in a mass ratio of 2:1.25.
[0072] Comparative Example 7:
[0073] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0074] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 2:0.5:0.06.
[0075] Comparative Example 8:
[0076] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0077] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: The plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 0.5:2:0.03.
[0078] Comparative Example 9:
[0079] Preparation of plant extracts: Lotus leaf extract, Rhizoma Cynomorii extract and Buddleja buddleja extract were mixed in a mass ratio of 1:0.25:0.5.
[0080] Preparation of a tyrosinase inhibitor whitening composition containing lotus leaf extract: the plant extract, heptapeptide II and paeonol are mixed in a mass ratio of 4:0.5:0.08.
[0081] Experiment 1: Effects of different compositions on tyrosinase activity
[0082] The tyrosinase activity is measured by the tyrosinase activity that catalyzes L-dopa to generate dopaquinone. The specific operation method refers to the contents disclosed in paragraphs
[0082] -
[0092] of patent CN109350578A, which is incorporated herein by reference, wherein the amount of whitening composition added is 1g, and the statistical results of the tyrosinase inhibition rate obtained are shown in Table 1:
[0083] Table 1 Tyrosinase inhibition rate of different compositions
[0084]
[0085]
[0086] It can be seen from the results in Table 1 that, compared with Example 7, the tyrosinase inhibition rate of the composition using heptapeptide II in Example 1 is significantly higher than that of heptapeptide I. Compared with Comparative Examples 1-3, the presence or absence of the strong red gate orchid extract and the buddleja extract in Example 1 has no obvious effect on the tyrosinase inhibition rate of the composition. Compared with Comparative Examples 4-6, it can be seen that the main active substances of the composition are plant extracts, especially lotus leaf extracts and small molecule peptides, and the adjuvants can improve the inhibition rate of the composition to tyrosinase to a certain extent. Compared with Comparative Examples 7-9, the mass ratio of the plant extract, small molecule peptide and adjuvant of the present invention is (1-3): (1-1.5): (0.01-0.05), which is the best amount ratio range claimed by the present invention. The content ratios of the three substances outside this range can reduce the inhibition rate of the composition to tyrosinase to a certain extent.
[0087] Experiment 2: Evaluation of the effects of different compositions in whitening serum
[0088] The whitening compositions of Examples 1 and 7 of the present invention and Comparative Examples 1-9 were respectively added into the essence formula shown in Table 2 below in an amount of 2.5 wt %.
[0089] Table 2 Whitening Essence Formula
[0090]
[0091]
[0092] The preparation process of the above whitening essence is as follows:
[0093] 1) Mix polysorbate 60, PEG-40 hydrogenated castor oil, polysorbate 20 and PPG-26-butanediol polyether-26, heat to 85° C., stir evenly and keep warm for 10 minutes to obtain product I;
[0094] 2) Mix deionized water, butylene glycol, panthenol, glycerin, disodium EDTA, xanthan gum, carbomer, ammonium acryloyldimethyltaurate / VP copolymer, and resveratrol, heat to 85° C., stir evenly, and dissolve completely to obtain product II;
[0095] 3) Preheat the emulsification pot and evaporate to dryness, pump product II into the emulsification pot, and pump product I into the emulsification pot under rapid stirring and homogenization, homogenize at 5000 rpm for 5 min, and then cool while stirring;
[0096] 5) Add arginine, sodium hyaluronate and citric acid at 45°C, homogenize for 5 minutes, and stir at 800 rpm to cool down;
[0097] 6) When the temperature drops to 35°C, add the whitening composition and essence, stir evenly, and cool to room temperature.
[0098] The whitening compositions of Example 1, Example 7 and Comparative Examples 1 to 9 were prepared into essences according to the above formula and method, and whitening effect evaluation tests were performed. The specific method is as follows:
[0099] 110 subjects aged between 25 and 40 with darker facial complexion were randomly selected and divided into 11 groups, with 10 subjects in each group. The essence prepared from the whitening composition of Examples 1, 7 and Ratios 1 to 9 was applied to the facial area every morning and evening, and each subject maintained basically the same diet and work and rest habits. The skin color difference test probe and (CL400, German CK), multifunctional skin test system (MPA580, German CK) and skin red and melanin tester and test probe (Mexameter MX18, German CK) were used to evaluate the changes in skin brightness and skin melanin content before and after the subjects used the essence. The average value was taken for each group, and the results are shown in Tables 3 to 4.
[0100] Table 3 Skin melanin MI value test results before and after using different essences
[0101]
[0102] Note: △MI=MInMI0; where MIn is the test value after using the sample in the test area; MI0 is the starting value of the test area.
[0103] As can be seen from Table 3, after using the whitening essences prepared in Examples 1 and 7 of the present invention and Comparative Examples 1-9, the skin melanin MI values were all reduced, indicating that the whitening essences prepared in Examples 1, 7 and Comparative Examples 1-9 all have the effect of reducing skin melanin. However, by comparing Example 1 with Comparative Examples 1-9, it was found that the whitening essence obtained in Example 1 of the present invention had the most obvious effect on reducing skin melanin.
[0104] Table 4 Statistical results of skin brightness L* value before and after using different essences
[0105]
[0106] Note: △L*=L*nL*0; where L*n is the test value after using the sample in the test area; L*0 is the starting value of the test area.
[0107] As can be seen from Table 4, after using the whitening essences prepared in Examples 1 and 7 of the present invention and Comparative Examples 1-9, the skin brightness L* values are all reduced, indicating that the whitening essences prepared in Examples 1, 7 and Comparative Examples 1-9 all have the effect of improving skin brightness. However, by comparing Example 1 with Comparative Examples 1-9, it is found that the whitening essence obtained in Example 1 of the present invention has the most obvious improvement on skin brightness.
[0108] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.
Claims
1. A tyrosinase inhibitor whitening composition containing lotus leaf extract, characterized in that: The whitening composition consists of a plant extract, a small molecule peptide and an auxiliary agent, wherein the mass ratio of the plant extract, the small molecule peptide and the auxiliary agent is (1-3): (1-1.5): (0.01-0.05).
2. The tyrosinase inhibitor whitening composition containing lotus leaf extract according to claim 1, characterized in that: The plant extracts include lotus leaf extract, cymbidium sibiricum extract and buddleja flower extract, and the mass ratio of the lotus leaf extract, cymbidium sibiricum extract and buddleja flower extract is 1:(0-0.5):(0-1).
3. The tyrosinase inhibitor whitening composition containing lotus leaf extract according to claim 1, characterized in that: The small molecule peptide is heptapeptide I, and the heptapeptide I is heptapeptide-6.
4. The tyrosinase inhibitor whitening composition containing lotus leaf extract according to claim 1, characterized in that: The small molecule peptide is heptapeptide II, and the heptapeptide II is acetyl heptapeptide-4.
5. The tyrosinase inhibitor whitening composition containing lotus leaf extract according to claim 1, characterized in that: The auxiliary agent is selected from any one of paeonol, bakuchiol, kaempferol and 4-butylresorcinol.
6. Use of the tyrosinase inhibitor whitening composition containing lotus leaf extract according to any one of claims 1 to 5 in the preparation of whitening cosmetics.
7. The use according to claim 6, characterized in that: The added mass of the tyrosinase inhibitor whitening composition containing lotus leaf extract in the whitening cosmetic is 0.5-5% based on the total mass of the whitening cosmetic.
8. The use according to claim 6, characterized in that: The whitening cosmetics include whitening skin care water, whitening essence, whitening lotion or whitening skin care cream.
9. The use according to claim 6, characterized in that: The whitening cosmetic also includes a moisturizer and a thickener; the moisturizer includes one or a combination of two or more of butylene glycol, panthenol, glycerol, dipropylene glycol, propylene glycol, polyethylene glycol-32, glyceryl polyether-26, and sodium hyaluronate; The thickener includes one or a combination of two or more of xanthan gum, behenyl alcohol, ammonium acryloyldimethyltaurate / VP copolymer, polyacrylamide, carbomer, and hydroxyethyl cellulose.
10. The use according to claim 6, characterized in that: The whitening cosmetic also includes a skin conditioner and a solubilizer; The skin conditioning agent is selected from one or a combination of two or more of citric acid, ceramide, arginine, resveratrol, and hydrogenated lecithin; The solubilizer is selected from one or a combination of two or more of polysorbate-60, polysorbate-20, PEG-40 hydrogenated castor oil, and PEG-60 hydrogenated castor oil.
Citation Information
Patent Citations
Skin-whitening, wrinkle-resisting and skin-protecting oil and preparing method thereof
CN105997612A
Cosmetic composition for acne improvement containing natural ingredients and ample type liquid cosmetics using thereof
KR1020180123799A
Semiconductor device manufacturing method including air gap
KR1020220040074A
Cited By
Repair composition and preparation and application of bionic liposome thereof
CN122182421A
